Introduction: A study sample of 78 manuscripts was selected from the 1,223 transferred from the 8^th Khalkha Jebtsundamba’s Library to the National Library of Mongolia. This sample consists of single, representative volumes from unique, multi-volume texts. Of the 78 manuscripts analyzed by Tungalag Batmunkh, eight (approx. 10%) are categorized as medical treatises. However, a systematic study conducted by Academician Bold Sharav identified a total of nine distinct volumes, thereby establishing a precise corpus of the works. One of these is the book “The book summarizes a number of conventional formulas from Tong Ren Tang Pharmaceutical Company”, which is one of the sources that has not yet been researched. This study was undertaken to determine the origin of the book, terminology, number, and category of medicines, and to clarify the drug action of some formulas.
To determine the origin, terminology, number, and classification of the ancient medical book “The book summarizes a number of conventional formulas from Tong Ren Tang Pharmaceutical Company,” and to clarify the characteristics of the medicines included in the chapter “Drugs for stroke diseases.” Methods: We employed methods such as the study of original texts and sources, and the checklist method. Conclusion The medications used in this book for stroke have the following benefits: thrombolytic, bone strengthening, tendon pain relief, support free breathing, relieve fever, antiplatelet, cure wind, regeneration bone marrow, improve testicle semen, and provide physical radiance, strength, and virility.

Background: The utility of hepatitis B immunoglobulin (HBIg) in hepatitis D virus (HDV)-reactivation prophylaxis remains contentious. This study compared liver transplant (LT) patients based on whether they received perioperative HBIg to assess its protective effect against HDV reactivation. Methods: Fifty-seven recipients with hepatitis B virus (HBV) and HBV/HDV, who were at least 1 year posttransplantation as of January 1, 2021, were enrolled in this single-center study. Tests for hepatitis B surface antigen (HBsAg), anti-HDV antibody, and quantitative reverse transcription polymerase chain reaction for HBV DNA and HDV RNA were performed. Interviews were conducted to assess compliance with the nucleos(t) ide analogue (NA) regimen and to document preoperative HBV/HDV status. Liver function tests were also carried out. The nonparametric Mann-Whitney U-test was utilized to determine statistical significance, with P<0.05 considered significant. Data analysis was conducted using GraphPad Prism software. Results: The prevalence of HDV RNA, HBV DNA, HBsAg, and anti-HDV positivity in the HBIg group (n=23) was 4.3% (n=1), 17.4% (n=4), 8.7% (n=2), and 95.7% (n=22), respectively. In the non-HBIg group (n=34), these rates were 5.9% (n=2), 8.8% (n=3), 11.8% (n=4), and 97.1% (n=33), respectively. Interviews revealed that all reactivations occurred in patients who were noncompliant with their NA regimen. Eleven of the 13 patients initially reported to be monoinfected with HBV pretransplantation were anti-HDV-positive. Conclusions No HDV replication occurred in either group due to spontaneous reactivation. High-efficacy NAs appear to be effective in sustaining HDV suppression postLT. Most recrudescent cases of chronic hepatitis D are mild and self-limiting, typically resolving after 1–2 years of replication, as evidenced by liver function tests.